De Yang

Title: The Innovative Contributions of De Yang

Introduction

De Yang is a prominent inventor based in Frederick, MD (US), known for his significant contributions to the field of cancer immunotherapy. With a total of 6 patents, his work focuses on developing novel therapeutic strategies to combat cancer.

Latest Patents

One of De Yang's latest patents is a human monoclonal antibody targeting tumor necrosis factor receptor 2 (TNFR2) for cancer immunotherapy. This antibody specifically binds to TNFR2 and promotes antibody-dependent cell-mediated cytotoxicity (ADCC) of human TNFR2CD4T regulatory cells in a dose- and time-dependent manner. Another notable patent involves a therapeutic antitumor combination of a Toll-like receptor (TLR) 4 ligand with other treatments. This method includes co-administration of TLR4 ligands, such as HMGN1 protein, along with TLR7 or 8 ligands and immune checkpoint inhibitors to enhance the immune response against cancer.

Career Highlights

De Yang has worked with the National Institutes of Health, a component of the US Department of Health & Human Services. His research has significantly advanced the understanding and treatment of cancer through innovative therapeutic approaches.

Collaborations

Throughout his career, De Yang has collaborated with notable colleagues, including Joost J Oppenheim and Michael Bustin. These collaborations have further enriched his research and contributed to the development of effective cancer therapies.

Conclusion

De Yang's innovative work in cancer immunotherapy exemplifies the impact of dedicated research and collaboration in the fight against cancer. His patents and contributions continue to pave the way for new therapeutic strategies that hold promise for improving patient outcomes.